Brian Reed: Hey. You saw the Post story.
Eliza Ward: Hard to miss. August 23rd, four days after the actual announcement. Patient profiles, including a 73-year-old tennis coach named Mark Orwig who enrolled in the melanoma trial — and the framing is basically: we are watching a revolution.
Brian Reed: The framing is doing a lot of lifting there.
Eliza Ward: It is, but — okay, the underlying news is genuinely significant. Moderna and Merck, August 19, announce that intismeran autogene combined with pembrolizumab cleared Phase 3. First mRNA cancer drug to reach that stage. That's not spin, that's a real milestone.
Brian Reed: No, I — right, I'm not disputing the milestone. The part I don't get is: Stéphane Bancel is calling this a new chapter in cancer care, and I'm wondering what data that claim is actually resting on, because they haven't published Phase 3 results anywhere yet.
Eliza Ward: Confirmed. They said results would go to a conference and then to regulators. Peer-reviewed journal — not yet.
Brian Reed: And the 44% recurrence reduction that's all over the coverage—
Eliza Ward: Phase 2. That's Phase 2 data. We don't know yet if Phase 3 matches it, beats it, or comes in softer. That gap is — wait, that's actually the whole story right now.
Brian Reed: That gap is exactly it. Think of it this way — the company announced they passed their final exam, but nobody outside the room has checked the answers yet. That's literally where we are.
Eliza Ward: And the 44% number everybody's quoting — that's not from the exam. That's from a practice test.
Brian Reed: Right. Phase 2. Which — I mean, Phase 2 is real, the hazard ratio of 0.56 is a real result, but it's a smaller trial, earlier stage, and we don't know if Phase 3 lands in the same place.
Eliza Ward: Could be stronger. Could be softer. We genuinely don't know.
Brian Reed: And the data hasn't been peer-reviewed, hasn't been published, hasn't even been presented at a conference yet as of August 19th. So when Stéphane Bancel is declaring a new chapter in cancer care, he's — I mean, he's getting ahead of what's been independently verified.
Eliza Ward: Though — wait, here's what I don't want to lose. The underlying science isn't speculative. Catherine Wu's team at Dana-Farber published proof-of-concept in 2017 showing personalized mRNA vaccines could actually generate mutation-specific T-cell responses. So the mechanism is real. The Phase 3 milestone is real. The number floating around just isn't from Phase 3.
Brian Reed: So the science has roots, the milestone happened — we're just waiting for the grade.
Eliza Ward: FDA review is what comes next. That's the actual next step. Not the celebration.
Brian Reed: And between now and that review — what does someone with high-risk melanoma actually do with this announcement? That's the question I can't shake.
Eliza Ward: That question is where the 'revolution' framing actually breaks. Because the therapy that helped Mark Orwig — the sequencing, the bespoke manufacturing, the cold chain — that's not a scalable pipeline. Every single dose of intismeran autogene is built from that specific patient's tumor. You cannot batch-produce it.
Brian Reed: What does that cost?
Eliza Ward: North of $100,000 per dose. Per patient. That's the estimate. And that's — wait, that's not a manufacturing inefficiency you fix by building a bigger facility. The personalization is the therapy. You can't standardize it away.
Brian Reed: So when Merck and Moderna call this a breakthrough in cancer care — I mean, a tennis coach in California with access to a major trial center is not most melanoma patients globally.
Eliza Ward: That's the correction. 'Revolutionary' implies reach. And the structural model here — sequence your tumor, build your vaccine, wait, administer — that is structurally easier in wealthy health systems with genomic infrastructure already in place. Dean Y. Li from Merck Research Laboratories has spoken to the trial's promise. The equity question? Not addressed.
Brian Reed: Not in the announcement, not in the coverage — the Post piece is warm, it's a human story, but it doesn't ask who else gets this.
Eliza Ward: And the thing that bothers me — actually, the thing I want to flag — is that melanoma is mutation-heavy. It's a strong target for neoantigen vaccines. Whether this holds in lung, breast, prostate — those 120-plus trials are running on hypothesis, not Phase 3 evidence. That's the question I don't think we can answer yet.
Brian Reed: So the part that comes later in all this — whether the Phase 3 data, when they're actually published, replicate that Phase 2 result in melanoma, and whether any of those other trials prove the platform works beyond a cancer that was already a good test case — that's not settled. At all.
Eliza Ward: And melanoma isn't just 'a good test case' — it's almost the best possible case. High mutational burden means the immune system has a lot of neoantigens to work with. A lot of targets. That's actually why Catherine Wu's team picked it. So the fact that we got a Phase 3 win there — that's meaningful, but it also sets a ceiling question: what happens in a cancer where the tumor isn't handing you that many targets to begin with?
Brian Reed: Like pancreatic. Or some lung subtypes.
Eliza Ward: Exactly those. And that's where the 120-plus ongoing trials — I mean, the number sounds big, but running trials and having Phase 3 data are not the same thing. Right now, no cancer type other than melanoma has cleared Phase 3. None.
Brian Reed: There is one early signal I want to name, though — actually, let me make sure I get this right. A 2024 first-in-human study, mRNA vaccines targeting the KRAS G12V mutation, combined with pembrolizumab, in patients with advanced solid tumors. Safety cleared, preliminary efficacy signal. That's not melanoma. That's pancreatic, colorectal, lung — KRAS shows up across a lot of cancers.
Eliza Ward: Wait — first-in-human. That's phase one territory. Safety and early signal.
Brian Reed: Yes. Which is — I mean, I'm not calling it validation. I'm calling it 'the most concrete thing we have' beyond melanoma. It's the difference between a hypothesis and a result you can point to, even an early one. The National Cancer Institute is funding research infrastructure under all of this. But the distance between that 2024 study and a Phase 3 data set is enormous.
Eliza Ward: And there's a separate problem that doesn't get much air. CNN flagged it — COVID mRNA vaccine skepticism is already attaching itself to this therapy in public conversation. Which means even if the FDA submission lands and peer-reviewed data publish cleanly, you've got a public trust gap that's got nothing to do with the science.
Brian Reed: That's — that's the part I find genuinely alarming. The clinical evidence is growing and the resistance is importing a different argument entirely.
Eliza Ward: So the concrete thing to watch: FDA submission, and specifically when Phase 3 data actually appear in a peer-reviewed journal — that's the moment a conference presentation becomes something regulators and oncologists can independently evaluate. Until that happens, the Phase 2 benefit of 44% is still the only published number. That's what separates what we know from what we're being asked to believe.
Brian Reed: So three conditions, right? Phase 3 peer-reviewed data actually confirm that 44% recurrence reduction. Manufacturing scales without — I mean, without collapsing what a health system can actually afford. And the platform proves it works in at least one other cancer type within five years. That's the frame. And as of August 19th, 2026, none of those three conditions is met. Not one.
Eliza Ward: None. And that's — wait, that's not skepticism about the science. That's just where the evidence is. The Phase 3 milestone happened. The peer-reviewed data haven't dropped. The manufacturing cost is still north of $100,000 per bespoke dose. And every trial beyond melanoma is still running on hypothesis. Those are the facts, not a knock on Moderna or Merck.
Brian Reed: Which brings me back to the question I actually can't answer. Someone with high-risk resected melanoma today — do they wait? Do they ask their oncologist about trial access? The announcement is real, the FDA submission is coming, but the treatment isn't available. What does a patient do with that gap?
Eliza Ward: That's the one I don't have a clean answer to. The 'revolution' claim becomes defensible only if all three hold — and we're probably looking at years before we know. That's the honest state of it.
